Literature DB >> 23242014

Mass spectrometric analysis of hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type O-linked glycosylation.

Joachim Bräutigam1, Axel J Scheidig, Wolfgang Egge-Jacobsen.   

Abstract

The infectious liver disease hepatitis C is caused by the small, enveloped, positive single-strand RNA hepatitis C virus (HCV). The HCV genome encodes for a single polyprotein precursor of ∼3010 amino acid residues. Host and cellular proteases co- and posttranslational process the precursor creating six nonstructural (NS) proteins and four structural components. Properly folded forms of the envelope proteins E1 and E2 form the associated E1-E2 complex. This complex represents a significant antigenic component at the viral surface that can interact with several target cell receptors. Extent and type of glycosylation is an important factor for virulence and escape from the immune system. Detailed characterization of the glycosylated sites is helpful for the understanding of different phenotypes as well as for the development of E1/E2-related treatments of HCV infection. Here, we have investigated in detail the O-linked glycosylation of the HCV envelope protein E2 expressed in and isolated from human embryonic kidney (HEK 293) cells. Using nano-liquid chromatography and tandem mass spectrometry approaches, we clearly have identified six residues for O-linked glycosylation within isolated glycopeptides (Ser393, Thr396, Ser401, Ser404, Thr473 and Thr518), carrying mainly Core 1 and Core 2 mucin-type structures. Based on our data, Thr385 is probably glycosylated as well. In addition, we could show that Ser479 within the hyper variable region (HVR) I is not O-glycosylated. For most of these sites, different degrees of microheterogeneity could be verified. Concerning HCV E2, this is the first case of experimentally proven O-linked glycosylation in detail via mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242014     DOI: 10.1093/glycob/cws171

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  16 in total

1.  Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA.

Authors:  Alla Kachko; Sandra Loesgen; Syed Shahzad-Ul-Hussan; Wendy Tan; Iryna Zubkova; Kazuyo Takeda; Frances Wells; Steven Rubin; Carole A Bewley; Marian E Major
Journal:  Mol Pharm       Date:  2013-11-07       Impact factor: 4.939

Review 2.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

3.  Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.

Authors:  Ieva Bagdonaite; Rickard Nordén; Hiren J Joshi; Sarah L King; Sergey Y Vakhrushev; Sigvard Olofsson; Hans H Wandall
Journal:  J Biol Chem       Date:  2016-04-15       Impact factor: 5.157

4.  Influenza A Virus-Induced Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication.

Authors:  Shoko Nakamura; Masayuki Horie; Tomo Daidoji; Tomoyuki Honda; Mayo Yasugi; Atsushi Kuno; Toshihisa Komori; Daisuke Okuzaki; Hisashi Narimatsu; Takaaki Nakaya; Keizo Tomonaga
Journal:  J Virol       Date:  2015-12-04       Impact factor: 5.103

5.  Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway.

Authors:  Miriam Triyatni; Edward A Berger; Bertrand Saunier
Journal:  World J Hepatol       Date:  2016-07-08

6.  Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Authors:  Christian K Mathiesen; Jannick Prentoe; Luke W Meredith; Tanja B Jensen; Henrik Krarup; Jane A McKeating; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

7.  A Biologically-validated HCV E1E2 Heterodimer Structural Model.

Authors:  Matteo Castelli; Nicola Clementi; Jennifer Pfaff; Giuseppe A Sautto; Roberta A Diotti; Roberto Burioni; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Nicasio Mancini
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

Review 8.  Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies.

Authors:  Emmanuelle V LeBlanc; Youjin Kim; Chantelle J Capicciotti; Che C Colpitts
Journal:  Pathogens       Date:  2021-06-01

Review 9.  Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.

Authors:  Giuseppe Sautto; Alexander W Tarr; Nicasio Mancini; Massimo Clementi
Journal:  Clin Dev Immunol       Date:  2013-07-09

Review 10.  Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Authors:  Thomas R Fuerst; Brian G Pierce; Zhen-Yong Keck; Steven K H Foung
Journal:  Front Microbiol       Date:  2018-01-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.